| Literature DB >> 26135739 |
Abstract
Entities:
Mesh:
Year: 2015 PMID: 26135739 PMCID: PMC4489653 DOI: 10.1371/journal.ppat.1004904
Source DB: PubMed Journal: PLoS Pathog ISSN: 1553-7366 Impact factor: 6.823
Vaccinia virus proteins involved in the formation and transport of EVs [reviewed in 2,4,5,8].
|
|
|
|---|---|
|
| Contributes to the formation and microtubule-mediated transport of the WVs. |
|
| Affects the incorporation of the B5 and A34 proteins into the outer membrane of EVs. |
| Required for the formation of actin-filled projections; required (with A36 proteins) on the surface of infected cells to interact with B5 proteins on EVs to promote actin-mediated transport of EVs. | |
|
| Loss of A34 protein results in a severe reduction in the number of WVs formed. |
| Affects EV release from cells and EV infectivity. | |
| Loss of the A34 protein increases the resistance of the outer membrane of EV to spontaneous rupture. | |
| Promotes the incorporation of the B5 protein into the WV/EV. | |
|
| Loss of A36 protein reduces the efficiency of WV transport to the plasma membrane. |
| Required for the formation of actin-filled projections; required (with A33 proteins) on the surface of infected cells to interact with B5 proteins on EVs to promote actin-mediated transport of EVs. | |
|
| Loss of B5 protein reduces the numbers of WVs formed. |
| Required for the formation of actin-filled projections; required to activate Src and phosphorylate the A36 protein to enable actin polymerization. | |
|
| Forms a complex with the F12 protein. |
| Involved in WV morphogenesis. | |
| Involved in microtubule-mediated transport of WVs to the plasma membrane. | |
| Loss of the E2 protein results in a significant reduction of EV formation. | |
|
| Through inhibition of RhoA signaling, F11 protein promotes cell motility and viral morphogenesis, as well as remodeling of cortical actin to facilitate virus transport to the plasma membrane. F11 protein promotes virus release from the cell, but this protein is not required for the production of EVs. |
|
| Forms a complex with the E2 protein. |
| Forms a complex with the A36 protein. | |
| Involved in WV morphogenesis. | |
| Involved in microtubule-mediated transport of WVs to the plasma membrane. | |
| Loss of the F12 protein results in a significant reduction of EV formation. | |
|
| Required for WV formation. |
| (The F13 protein is the target of the antipoxviral drug ST-246). |
* Cowpox virus mutants lacking the ability to encode these proteins produced white pocks on the CAM [27].
**A cowpox virus mutant lacking the ability to encode the F13 protein failed to produce any pocks on the CAM [27].
Fig 1The advance guard model of poxvirus infection.
EVs are actively released from intact infected cells and propelled from those cells to outpace the spread of antiviral cytokines, interferons, proinflammatory cytokines, PAMPs, and DAMPs, which are subsequently released from infected cells, and which may initiate innate immune responses from resident or infiltrating sentinel cells. This mechanism may also enable productive infections of neighboring cells that might otherwise be rendered refractive to viral replication by interferons and danger signals released from cells at the site of the primary infection. Cell-associated EVs carried long distances from the primary site of infection by motile cells may similarly be able to initiate infections in the absence of accompanying danger signals.